Intellia Therapeutics, Inc. Share Price
NASDAQ: NTLA | Small CapIntellia Therapeutics, Inc. Stock Performance
Open $11.80 | Prev. Close $11.93 | Circuit Range N/A |
Day Range $11.76 - $12.24 | Year Range $7.95 - $28.25 | Volume 1,10,186 |
Average Traded $12.05 |
Intellia Therapeutics, Inc. Share Price Today
As of 11 August 2026, Intellia Therapeutics, Inc.'s share price is $12.02. The stock opened at $11.80, compared to its previous close of $11.93. During today's trading session, Intellia Therapeutics, Inc.'s share price traded between $11.76 and $12.24, with an average price of $12.00. Over the past 52 weeks, the stock has recorded a high of $28.25 and a low of $7.95. In terms of performance, Intellia Therapeutics, Inc.'s share price has declined by 12.77% over the last six months and is up 5.90% on a year-on-year basis.
Intellia Therapeutics, Inc. Share Price Chart
Intellia Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $1.30B | PE Ratio (TTM) -3.15 | Dividend Yield N/A |
EPS (TTM) $-3.81 | Revenue (TTM) $67.67M | Return On Equity (TTM) -61.47% |
Profit Margin -609.85% | Debt to Equity 0.15 | Quarterly Earnings Growth YoY 25.34% |
Intellia Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Intellia Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Intellia Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $10.64 | $11.95 | +11.89% |
Jul 2026 | $17.15 | $10.68 | -36.92% |
Jun 2026 | $13.78 | $16.93 | +20.33% |
May 2026 | $13.27 | $14.07 | +4.49% |
Apr 2026 | $13.03 | $13.46 | +5.11% |
Mar 2026 | $13.80 | $12.81 | -7.04% |
Feb 2026 | $13.01 | $13.78 | +4.91% |
Jan 2026 | $9.21 | $13.13 | +46.27% |
Dec 2025 | $8.72 | $8.98 | -0.11% |
Nov 2025 | $13.07 | $8.99 | -28.74% |
Oct 2025 | $17.38 | $12.62 | -26.95% |
Sep 2025 | $11.19 | $17.27 | +52.16% |
NTLA Share Price FAQs
What is Intellia Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Intellia Therapeutics, Inc. stock?
What is NTLA's market capitalisation today?
What is NTLA's net income for the last quarter?
What is the 5 year returns of NTLA?
What is the high & low stock price of NTLA today?
Can I buy NTLA shares in India?